Male Breast Cancer Completed Phase 2 Trials for Sorafenib (DB00398)

IndicationStatusPhase
DBCOND0028546 (Male Breast Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00096434Sorafenib in Treating Patients With Metastatic Breast CancerTreatment